ATUL2024-07-012024-09-30 ATUL2024-07-012024-09-30 ATUL2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member ATUL2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member ATUL2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member ATUL2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member ATUL2024-09-30 ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue03Member ATUL2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member ATUL2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member ATUL2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue03Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults03Member ATUL2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member ATUL2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member ATUL2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults03Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets03Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member ATUL2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member ATUL2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member ATUL2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member ATUL2024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member ATUL2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ATUL2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ATUL2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ATUL2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ATUL2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ATUL2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member ATUL2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member ATUL2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500027 ATUL NOTLISTED Atul Limited Equity 2024-04-01 2025-03-31 2024-10-25 2024-09-25 INR Crores Half yearly 10:00:00 13:15:00 2024-10-25 2024-10-25 true Cash Flow Indirect Not applicable Multi segment 2024-07-01 2024-09-30 Unaudited Consolidated 13928300000.00 315200000.00 14243500000.00 7240700000.00 116300000.00 -818600000.00 1183500000.00 88900000.00 775400000.00 3779000000.00 12365200000.00 1878300000.00 0.00 1878300000.00 408000000.00 106400000.00 514400000.00 0.00 1363900000.00 0.00 0.00 0.00 31400000.00 1395300000.00 1796100000.00 3191400000.00 1368100000.00 27200000.00 1796100000.00 0.00 294400000.00 10 46.47 46.47 0.00 0.00 46.47 46.47 1. These results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on October 24, 2024 and approved by the Board of Directors in its meeting held on October 25, 2024. The Statutory Auditors have carried out a limited review of the consolidated unaudited financial results for the quarter six months ended on September 30, 2024. Their limited review report does not have any modification. 3. The Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below: Name of segment Main product groups Life Science Chemicals Active pharmaceutical ingredients and its intermediates, crop protection chemicals Performance and Other Chemicals Adhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyes Others Agribiotech, food products, services and others Multi segment 2024-04-01 2024-09-30 Unaudited Consolidated 27148800000.00 445600000.00 27594400000.00 14203100000.00 284000000.00 -1344500000.00 2233200000.00 142700000.00 1541200000.00 7113300000.00 24173000000.00 3421400000.00 0.00 3421400000.00 801400000.00 168200000.00 969600000.00 0.00 2451800000.00 0.00 0.00 0.00 64200000.00 2516000000.00 3043400000.00 5559400000.00 2486900000.00 29100000.00 3043400000.00 0.00 294400000.00 10 84.47 84.47 0.00 0.00 84.47 84.47 Other Expenses 2044000000.00 Power, fuel and water 1735000000.00 Other Expenses 3867900000.00 Power, fuel and water 3245400000.00 519400000.00 27589200000.00 2119500000.00 32200000.00 291400000.00 22600000.00 220400000.00 522400000.00 11897200000.00 2600000.00 178100000.00 12077900000.00 190800000.00 1367200000.00 44433600000.00 8077600000.00 5028200000.00 10844000000.00 588500000.00 131800000.00 0.00 621400000.00 17213900000.00 1850400000.00 27141900000.00 71575500000.00 294600000.00 55791300000.00 56085900000.00 56605300000.00 1910800000.00 98000000.00 2008800000.00 288500000.00 2518000000.00 9600000.00 4824900000.00 216000000.00 7377100000.00 1666600000.00 9259700000.00 592400000.00 240300000.00 52900000.00 10145300000.00 14970200000.00 71575500000.00 1. These results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on October 24, 2024 and approved by the Board of Directors in its meeting held on October 25, 2024. The Statutory Auditors have carried out a limited review of the consolidated unaudited financial results for the quarter six months ended on September 30, 2024. Their limited review report does not have any modification. 3. The Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below: Name of segment Main product groups Life Science Chemicals Active pharmaceutical ingredients and its intermediates, crop protection chemicals Performance and Other Chemicals Adhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyes Others Agribiotech, food products, services and others Life Science Chemicals 4077500000.00 Others 186300000.00 Performance and other chemicals 10236800000.00 Life Science Chemicals 8313800000.00 Others 380400000.00 Performance and other chemicals 19623000000.00 14500600000.00 28317200000.00 572300000.00 1168400000.00 13928300000.00 27148800000.00 Life Science Chemicals 836000000.00 Others 26700000.00 Performance and other chemicals 989600000.00 Life Science Chemicals 1545700000.00 Others 77000000.00 Performance and other chemicals 1841100000.00 1852300000.00 3463800000.00 88900000.00 142700000.00 -144900000.00 1. These results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on October 24, 2024 and approved by the Board of Directors in its meeting held on October 25, 2024. The Statutory Auditors have carried out a limited review of the consolidated unaudited financial results for the quarter six months ended on September 30, 2024. Their limited review report does not have any modification. 3. The Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below: Name of segment Main product groups Life Science Chemicals Active pharmaceutical ingredients and its intermediates, crop protection chemicals Performance and Other Chemicals Adhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyes Others Agribiotech, food products, services and others -164500000.00 1908300000.00 3485600000.00 Life Science Chemicals 13410500000.00 Others 2249500000.00 Performance and other chemicals 37154200000.00 52814200000.00 18761300000.00 71575500000.00 Life Science Chemicals 3281800000.00 Others 231500000.00 Performance and other chemicals 8080600000.00 11593900000.00 3376300000.00 14970200000.00 142700000.00 -1907800000.00 0.00 -1440900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1683900000.00 0.00 1541200000.00 0.00 0.00 0.00 0.00 0.00 71400000.00 0.00 0.00 0.00 -177500000.00 0.00 0.00 0.00 -26100000.00 0.00 -113100000.00 3308300000.00 -78000000.00 0.00 -46100000.00 663300000.00 0.00 2520900000.00 0.00 0.00 0.00 124100000.00 0.00 0.00 0.00 0.00 2800000.00 1584500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 800000.00 5400000.00 0.00 0.00 165500000.00 4500000.00 0.00 -95800000.00 0.00 -1627000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 191700000.00 0.00 6300000.00 588900000.00 132500000.00 0.00 -200000.00 -919600000.00 -25700000.00 11600000.00 -14100000.00 602600000.00 588500000.00 Fair value of equity instruments through other comprehensive income 2094600000.00 Remeasurement gain|(loss) on defined benefit plans 46900000.00 Fair value of equity instruments through other comprehensive income 3506400000.00 Remeasurement gain|(loss) on defined benefit plans 19400000.00 2141500000.00 3525800000.00 423200000.00 568800000.00 Effective portion of gain | (loss) on cash flow hedges -800000.00 Exchange differences on translations of foreign operations 79400000.00 Effective portion of gain | (loss) on cash flow hedges -2200000.00 Exchange differences on translations of foreign operations 78600000.00 78600000.00 76400000.00 800000.00 -10000000.00